Reported in over 90% of pancreatic cancers, 33% of colon cancers, 32% of lung cancers, and 31% of biliary tract cancers, KRAS is mutated in some of the most treatment-resistant solid tumors [33]. Here, KRAS is linked to lung carcinoma.